Mechanism of Off-Target Interactions and Toxicity of Tamoxifen and Its Metabolites

被引:16
作者
Flynn, Maria [1 ]
Heale, Kali Amelia [1 ]
Alisaraie, Laleh [1 ,2 ]
机构
[1] Mem Univ Newfoundland, Sch Pharm, St John, NF A1B 3V6, Canada
[2] Mem Univ Newfoundland, Dept Chem, St John, NF A1B 3X7, Canada
关键词
MUSCARINIC ACETYLCHOLINE-RECEPTOR; SURGICAL ADJUVANT BREAST; INCREMENTAL CONSTRUCTION; DOPAMINE-RECEPTOR; DRUG-THERAPY; CANCER; DOCKING; BINDING; PHARMACOKINETICS; PREVENTION;
D O I
10.1021/acs.chemrestox.7b00112
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tamoxifen is an estrogen modulator that acts to competitively inhibit the binding of endogenous estrogens. It is widely used for treatment of breast cancer; however, analogous with many antineoplastic agents, tamoxifen is associated with numerous adverse effects, most prominently nausea. We have identified several off-target receptors of tamoxifen and 22 of its metabolites that include histamine H1 and H3, and muscarinic M1, M4, and M5 subtypes, and dopamine D2 receptor. We have shown how they are associated with tamoxifen and its metabolites' toxicity through a comprehensive computational analysis of their interaction modes, which were also compared to that of the related endogenous substrates of each receptor. The results were further evaluated using available in vivo and in vitro data. The presented work provides foundational knowledge toward the determination of the precise mechanism of nausea induction, and in particular, interactions of tamoxifen and its metabolites with the receptors involved in that biomolecular pathway. This study can assist in predicting the potential undesired effects of the chemicals with common pharmacophores or similar fragments to that of tamoxifen and its metabolites and serve drug discovery research in developing more effective and tolerable tamoxifen analogues or chemotherapeutic agents.
引用
收藏
页码:1492 / 1507
页数:16
相关论文
共 45 条
  • [21] Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care
    Jager, N. G. L.
    Rosing, H.
    Schellens, J. H. M.
    Linn, S. C.
    Beijnen, J. H.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 477 - 483
  • [22] The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists
    Kalani, MYS
    Vaidehi, N
    Hall, SE
    Trabanino, RJ
    Freddolino, PL
    Kalani, MA
    Floriano, WB
    Kam, VWT
    Goddard, WA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (11) : 3815 - 3820
  • [23] Protein structure prediction on the Web: a case study using the Phyre server
    Kelley, Lawrence A.
    Sternberg, Michael J. E.
    [J]. NATURE PROTOCOLS, 2009, 4 (03) : 363 - 371
  • [24] Tamoxifen:: 28-day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects
    Kennel, P
    Pallen, C
    Barale-Thomas, E
    Espuña, G
    Bars, R
    [J]. ARCHIVES OF TOXICOLOGY, 2003, 77 (09) : 487 - 499
  • [25] Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
    Kiyotani, Kazuma
    Mushiroda, Taisei
    Imamura, Chiyo K.
    Hosono, Naoya
    Tsunoda, Tatsuhiko
    Kubo, Michiaki
    Tanigawara, Yusuke
    Flockhart, David A.
    Desta, Zeruesenay
    Skaar, Todd C.
    Aki, Fuminori
    Hirata, Koichi
    Takatsuka, Yuichi
    Okazaki, Minoru
    Ohsumi, Shozo
    Yamakawa, Takashi
    Sasa, Mitsunori
    Nakamura, Yusuke
    Zembutsu, Hitoshi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1287 - 1293
  • [26] Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
    Kuiper, GGJM
    Carlsson, B
    Grandien, K
    Enmark, E
    Haggblad, J
    Nilsson, S
    Gustafsson, JA
    [J]. ENDOCRINOLOGY, 1997, 138 (03) : 863 - 870
  • [27] PROCHECK - A PROGRAM TO CHECK THE STEREOCHEMICAL QUALITY OF PROTEIN STRUCTURES
    LASKOWSKI, RA
    MACARTHUR, MW
    MOSS, DS
    THORNTON, JM
    [J]. JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1993, 26 : 283 - 291
  • [28] Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
    Muerdter, T. E.
    Schroth, W.
    Bacchus-Gerybadze, L.
    Winter, S.
    Heinkele, G.
    Simon, W.
    Fasching, P. A.
    Fehm, T.
    Eichelbaum, M.
    Schwab, M.
    Brauch, H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 708 - 717
  • [29] Drug therapy - Tamoxifen in the treatment of breast cancer
    Osborne, CK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) : 1609 - 1618
  • [30] The predicted 3D structures of the human M1 muscarinic acetylcholine receptor with agonist or antagonist bound
    Peng, Joyce Yao-chun
    Vaidehi, Nagarajan
    Hall, Spencer E.
    Goddard, William A., III
    [J]. CHEMMEDCHEM, 2006, 1 (08) : 878 - 890